TrialDiabetes2012

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

S Alice Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.